Details of the Drug

General Information of Drug (ID: DM1BRWD)

Drug Name
Concizumab
Indication
Disease Entry ICD 11 Status REF
Haemophilia A 3B10.0 Phase 3 [1]
Haemophilia B 3B11.0 Phase 3 [1]
Drug Type
Monoclonal antibody
Cross-matching ID
TTD ID
D2FE7T
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tissue factor pathway inhibitor (TFPI) TT068JH TFPI1_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Haemophilia A
ICD Disease Classification 3B10.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Tissue factor pathway inhibitor (TFPI) DTT TFPI 1.27E-08 0.14 0.84
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT05135559) Open-label Study Investigating Efficacy, Safety and Pharmacokinetics of Concizumab Prophylaxis in Children Below 12 Years With Haemophilia A or B With or Without Inhibitors. U.S.National Institutes of Health.
2 Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results. Blood. 2019 Nov 28;134(22):1973-1982.